Shire reports Fosrenol “significantly” reduces tablet burden

Shire has announced the findings of a new study which says that end-stage renal disease (ESRD) patients who use Fosrenol to reduce their phosphate absorption, instead of other phosphate-binders, could reduce their tablet burden “significantly”.

The report, unveiled at the National Kidney Foundation’s 2006 clinical meeting in Chicago, a large scale phase IV multicentre trial, found that both patients and physicians preferred Fosrenol over calcium based-phosphate binders and sevelamer hydrochloride.

Nirupama Vermur, MD, South Florida Nephrology Group, said: ?Successfully managing hyperphosphatemia is a challenge for most ESRD patients due to the exceedingly restrictive diet they must follow and the high tablet burden associated with traditional phosphate binder therapies.?

He added: ?By significantly reducing phosphate binder tablet burden, Fosrenol may help improve patient compliance, as well as clinical outcomes for patients with hyperphosphatemia.?

Last week, UK-based Shire petitioned the FDA to tighten the regulations for marketing generic versions of Adderall XT, which Shire also produces. Shire is set to publish its financial results on Thursday, within hours of those of its two main British competitors ? namely GlaxoSmithKline and AstraZeneca.

© Adfero Ltd